What to expect as the virus continues

--  |   08/04/2020 Text size  Decrease  Increase   |  
<p>As the coronavirus continues to spread and impact both the health of humanity and the economy, our healthcare strategist, Karen Andersen, sat down with director of personal finance Christine Benz to share her analysis of the impacts and government response. More states have issued stay-at-home orders, and more than 100,000 tests are being performed every day in efforts to reduce the number of cases as well as restrictions. A recent&nbsp;<a href="https://www.morningstar.com/articles/971254/morningstars-view-the-impact-of-coronavirus-on-the-economy">paper by Andersen and equity analyst Preston Caldwell</a>&nbsp;highlights several treatments in clinical trials for an effective treatment for the virus.&nbsp;&nbsp;<br /><br />While the waves of the virus and social distancing measures are projected to continue into the second half of the year, the economic impact is not expected to be long term. Maintaining social distancing measures to contain the virus is the main priority--along with the ability to use various apps to track the locations of people who have contracted the virus. Technology is imperative during the quarantine as businesses work remotely and research on the virus continues. On that same note, limitations are present: the shortage of ventilators and beds in the ICU. Companies are trying to respond quickly to increase capacity, but it is likely that the virus may overlap them. The worst wave is expected to hit in April. Improvement at the beginning of May can be expected if social distancing orders are obeyed, possible treatments continue to be tested, and the capacities of hospitals increase.&nbsp;</p> <p><em>Please stay tuned for important disclosure information at the conclusion of this video.</em></p> <p><strong>Christine Benz:</strong>&nbsp;Karen Andersen, who's a strategist in equity and credit research was with us&nbsp;<a href="https://www.morningstar.com/articles/972435/market-economic-implications-amid-latest-virus-news">three weeks ago</a>. She's back today and she's going to kick things off for us by providing an updated view on where we stand in terms of stopping the spread of the virus as well as the economic implications. So Karen will discuss developments that she and the team are seeing in terms of testing and vaccinations, therapies, as well as some of the equipment shortages that we've seen in the healthcare arena.</p> <p>Karen, please take it away.</p> <p><strong>Karen Andersen:</strong>&nbsp;Thanks Christine. Now that we have more information on how a coronavirus is spreading in different countries and more information on how governments are responding, my equity research colleague Preston Caldwell and I have updated our March 9 analysis. So our new report was published Tuesday, and it really tries to dive a little deeper into how this virus is affecting our health and our economy. So as far as health, we've refined our U.S. scenarios to get a month-by-month forecast of how the infection could spread and how widely the social distancing measures will be spread across the states.&nbsp;</p> <p>Just first, maybe a few updates on what we're doing to slow the spread of the virus right now. Almost half of Americans were under stay-at-home orders as at the end of March. And I believe that that dramatically increased in the past two days, as we've seen several more states issuing these kinds of orders. Our access to diagnostics is improving rapidly. So we now have more than a hundred thousand tests being performed each day in the U.S. so that brought us from March, I think, up to a million tests total. Both of these facts lead us to believe that our current efforts are allowing us to begin to reduce the number of cases possibly by early May and begin to slowly lift restrictions this summer, June and July. We do think we'll have confirmation of at least one effective treatment during the summer, which should give us more confidence even if we start to see some outbreaks again as we lift these restrictions, we won't see a replay of the shortages that we're currently seeing with ventilators in New York.&nbsp;</p> <p>Maybe just a little bit more on the treatment. So, the FDA actually just did sign off on March 28th on emergency use of two versions of an antimalarial drug to treat coronavirus. These drugs appear to act as antivirals in this case, and they have supportive data in some small studies so far. So hydroxychloroquine is being used widely in hospitals to help healthcare workers stay healthy and to treat patients as part of clinical trials or with this emergency approval. But there are also several other treatments that are now in clinical trials that we've updated in our new report. So Gilead's remdesivir remains the leading hope for an effective treatment, with data expected later this month from controlled studies in China, data from a handful of patients in different countries for remdesivir so far has been encouraging, but it's not definitive. So we're waiting for these studies that have a control arm to give us more indication. We model a 70% probability of approval for that drug.&nbsp;</p> <p>Two arthritis therapies are now also in clinical trials. These could help very sick patients with lung inflammation recover more quickly or avoid a ventilator, which is very important if we're facing these kinds of shortages. These therapies are widely available, and they could be quickly repurposed for coronavirus. And they only would require one dose that is being used in trials versus arthritis patients who typically require a dose every couple of weeks. Then in the long run, the pipeline is starting to shape up with the potential also for more-targeted drugs that are specifically designed against coronavirus by the end of the year and then vaccines in early 2021. I think JNJ was one of the latest firms that talked about accelerating their vaccine timelines, and they've guided now to an early 2021 time frame. That would be really roughly a one-year development time for a vaccine, and that would be at the faster end of that 12 to 18 months that a lot of companies have cited for coming up with a vaccine.</p> <p>The way I'm looking at this is that we will have waves of the virus and additional social distancing waves in the second half of the year, but not at the level of what we're doing right now, given the future availability of treatments. In addition, we'll have waves of new treatments after that, starting with repurposed drugs, Gilead's drug, targeted antibodies, and then ultimately a vaccine in 2021.&nbsp;</p> <p>Just very briefly turning to the economic impact. Our conclusions here are fairly similar to our previous report. We did increase the GDP impact we model for 2020, and we do now assume a 2.4% contraction in GDP in our base case. But we think the scope of the shutdown to disrupt the U.S. economy long-term is likely overrated. About 70% of GDP is actually from businesses that are mostly exempt from orders, and half of the businesses that aren't exempt can continue with remote operations. Also the fiscal stimulus should prevent a collapse on demand of the U.S. economy. That's our really our latest take on overall health and economic impact, Christine.</p> <p><strong>Benz:&nbsp;</strong>Karen, question for you: In terms of vaccines and therapies, let's talk about your sort of bear case if things don't unfold as you expect them to in the second half of the year.&nbsp;</p> <p><strong>Andersen:</strong>&nbsp;In a bear-case scenario, we do assume that there would be no effective treatment. And we also assume that we would be struggling a bit more to try to contain it even with this kind of first pass of social distancing measures. The other fact is that if we are struggling and there are no treatments, there's really only so long that we can try to hold on to this really aggressive shutdown of the country. I think that that probably would be limited to a few months as opposed to a year shutdown of the entire country.&nbsp;</p> <p>I do think that one thing that's important to remember, though, in this kind of scenario is the kind of tools that have been used in certain countries in Asia to prevent and control outbreaks. I'm thinking of countries like South Korea and Singapore. So what they do is they actually very aggressively trace contacts of those who become infected and then quarantine those who may have been exposed. And so now, just recently there's really been kind of an explosion in technology to help with this. And so there are various apps that can be used to track locations and then really determine who was close enough to someone who became infected that they need to self-quarantine. So this sort of information is really critical. Especially if we're in a situation where we've already contained the virus, and we're trying to emerge from a lockdown, and we don't have any kind of effective treatment.&nbsp;</p> <p>A big question here, though, is whether Americans are willing to accept the kind of privacy rights' violation issues that would come with this. I think one solution, though, could be to make these apps voluntary. And so if the situation remains really dire, I would hope that we would see a lot of folks volunteering to allow their maybe anonymized location data to be shared. So I think that even if we're really struggling with some of the social distancing measures, and even if we're not sure which treatment is best, I think there's probably a lot we can start to do, a progress we can make with technology, assuming Americans can get on board with this and start using their phones as something to help us fight the disease.</p> <p><strong>Benz:</strong>&nbsp;Karen, question for you about these ventilator shortages, which you briefly mentioned. Can you discuss your thoughts about how that will unfold in the coming months if these shortages aren't just limited to New York but other cities as well?</p> <p><strong>Andersen:</strong>&nbsp;Yeah, sure, Christine. New York, as of the data that we had on Tuesday, that was about 40% of U.S. cases and I think about 20% of all U.S. cases were in New York City alone. Having so many cases centered in one region or one city is frightening. There are so many limitations on what the healthcare system can handle from the number of ventilators, to even the number of healthcare workers trained to monitor patients on ventilators, to the number of ICU beds that these patients might need. We're seeing ventilator manufacturers trying to quickly increase capacity. Most of these companies are looking at something on the order of doubling their capacity. But this isn't really likely to come fast enough for this worst of the wave that's hitting us in April. But in our base- and bull-case scenarios, both of those scenarios, we think a ramped-up production of ventilators, potential new treatments, and better containment could all help improve the situation beginning in May.</p> <p>There are also a lot of creative ways that supply could be boosted faster. The FDA has already taken some steps here. They're allowing sleep apnea positive airway machines to be used in severe coronavirus patients. They're also using tube splitters, so that allows patients to share ventilators. Then also we've seen industries volunteer to make simplified ventilators that I wouldn't have really considered like auto industry or Dyson, the expert in vacuums. April will likely be very tough. But there are several ways that we can improve supply and reduce demand by having treatments beyond April.</p> <p><em>&copy;2020 Morningstar, Inc.. All Rights Reserved. The Morningstar name and logo are registered marks of Morningstar, Inc.</em></p> <p><em>This video contains certain forward-looking statements. We use words such as &ldquo;expects&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;, &ldquo;estimates&rdquo;, &ldquo;forecasts&rdquo;, and similar expressions to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially and/or substantially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.</em></p> <p><em>The information in this video is for informational purposes only and has no regard to the specific investment objectives, financial situation or needs of any specific recipient. This video is intended to provide information to assist investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: recipients must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.</em></p> <p><em>Opinions expressed are as of date this video was recorded; such opinions are subject to change without notice. Morningstar and its subsidiaries shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information, data, analyses, and opinions presented herein do not constitute investment advice, are provided solely for informational purposes and therefore are not an offer to buy or sell a security. Please note that references to specific securities or other investment options within this piece should not be considered an to purchase or sell that specific investment.</em></p> <p><em>It is important to note that investments in securities involve risk and will not always be profitable. There can be no assurance that any financial strategy will be successful.</em></p> <p><em>Christine Benz is an employee of Morningstar, Inc.</em></p> <p><em>Karen Andersen is an employee of Morningstar Research Services LLC. Investment research is produced and issued by subsidiaries of Morningstar, Inc. including, but not limited to, Morningstar Research Services LLC, registered with and governed by the U.S. Securities and Exchange Commission. The opinions expressed are given in good faith, are as of the date this video was recorded, and are subject to change without notice. The analysis presented are statements of opinions; they are not statements of fact. Analysts have made a reasonable effort to carefully research information contained in the video.</em></p> <p><em>The information on which the analysis is based has been obtained from sources believed to be reliable. While the data, statistics and information were obtained from sources it believes to be reliable, neither the Research group nor Morningstar, Inc. performs an audit or seeks independent verification of any of the data, statistics, and information it receives.</em></p> <p><em>The information contained in this video is the proprietary material of Morningstar. Reproduction, transcription, or other use, by any means, in whole or in part, without the prior written consent of Morningstar, is prohibited.</em></p>

Video Archive...

Three sustainable global equities with Anthony Doyle
29/06/2022  Firetrail's head of investment strategy talks through his global equity picks in the sustainable space. 
"Depends what the separation looks like": Morningstar on Suncorp's demerger plans
28/06/2022  While the benefits of the current model are modest, a demerger won't deliver shareholders an automatic win, says Morningstar equity analyst Nathan Zaia.
Hunker down but the turn isn't far away: Schroders' Simon Doyle
24/06/2022  "I think over the next sort of, three, six, nine months, we're going to see some pretty good opportunities emerge, and I think investors who are well prepared will be able to take advantage of that."
Miners not yet cheap: Morningstar explains the iron ore rout
23/06/2022  Policy will continue to fuel short-term price movements but the long-term fundamentals for Australia's biggest export look shaky.
Anton Tagliaferro on companies to weather the market storm
17/06/2022  The founder of Investors Mutual is cool on Australia's banking giants.
Why are banks selling off as rates rise? Morningstar explains
15/06/2022  Faster interest rate hikes from the Reserve Bank have markets worried about bad debts, says Morningstar banking analyst Nathan Zaia.
"Real chance we've broken the system as it was": Platinum backs regime change
14/06/2022  Highly likely investors are on the cusp of an era of permanently higher rates that should favour "real-world companies", says Andrew Clifford, co-chief investment officer at Platinum Asset Management.
"Get defensive": Warnes on where and when to put cash to work
14/06/2022  Build cash and prepare for opportunistic nibbles at companies such as Aurizon, Wesfarmers and James Hardie, says Morningstar's head of equity research.
"I'm still nervous": Peter Warnes on the outlook for equities
10/06/2022  We haven't seen the bottom of the bear market yet, says Morningstar's head of equity research.
From nosebleed to reason: US tech valuations looking attractive
01/06/2022  Earnings growth remains market leading for wide moat stocks like Alphabet, Meta Platforms and Amazon.
Will the election dampen the Australian resource sector?
30/05/2022  Labor looks set to proceed incrementally and existing producers such as Whitehaven Coal could even benefit should more radical policy be proposed.
'We don't learn': Morningstar sits with King Nudge Richard Thaler
25/05/2022  The Nobel prize winner who cameo'd alongside Selena Gomez in Hollywood hit The Big Short  discusses the latest developments in behavioural economics.
Why are Coles, Woolworths and JB Hi-Fi tanking? Morningstar explains
19/05/2022  Local investors were spooked after US retail giants Target and Walmart plummeted overnight as rising prices hit margins and inventory.
Dan Kemp's best tip for successful long-term investing: Beware market narratives
19/05/2022  On his recent visit to Australia, Morningstar's global chief investment officer Dan Kemp talks investing narratives, confronting the growing list of reasons to be concerned about markets and sustainable investing.
What's driving the latest big drop in US stocks?
19/05/2022  Worries about inflation’s toll on earnings sparks Wednesday’s 4% plunge, but stocks are now far undervalued.
Value strikes back: How to manage style in your portfolio
18/05/2022  One of the big themes of the year has been the value comeback. What is behind this resurgence after a pretty dismal period, and should your portfolio be tilting in its direction?
Is it time to recession-proof your portfolio?
11/05/2022  Here's what investors who are worried about a recession should consider today.
Morningstar Best Ideas List: An undervalued play in telecom
11/05/2022  Morningstar analysts have identified TPG telecom as the most undervalued telecom stocks in the ASX 200 detailing multiple catalysts for earnings recovery and growth.
Bill Browder: A scared Putin will only escalate the conflict
29/04/2022  Exclusive: Hermitage Capital Management CEO Bill Browder talks Putin, Russia, and the next six months for Ukraine
5 risks facing the US market right now
28/04/2022  Inflation, rising interest rates, geopolitical risks, and other things to keep your eye on.
Buffett and Berkshire in 2022
27/04/2022  Morningstar's analyst talks about the Buffett's recent deals, what the stock is worth, and whether Berkshire will pay a dividend any time soon.
Fair value upgrades on the table: Morningstar resources update
31/03/2022  Supply disruptions following Russia's invasion of Ukraine are forcing analysts to consider the possibility elevated prices persist.
Bank outperformance speaks to positive trajectory: Morningstar
30/03/2022  Rising interest rates, strong economic growth and cheaper valuations are driving banking stocks ahead of the broader market.
Stock vs stock: Netflix and Disney
28/03/2022  Where are entertainment and streaming services headed?
Morningstar Best Ideas List: WiseTech looks cheap after tech selloff
24/03/2022  Problems in global supply chains are an opportunity for WiseTech as its logistics company customers move to replace old software.
First fires, then floods: How listed insurers are weathering extreme events
23/03/2022  Markets focused on floods and bushfires are missing how insurers are cutting costs, doing more digitally and are looking down the barrel of a lift in investment income.
Don't get 'whipsawed' by false promises of peace in Europe
17/03/2022  Morningstar Investment Management's global CIO Dan Kemp explains why well-intentioned investors desperate for peace in Europe are making dangerous market calls
Morningstar Best Ideas List: Kogan to hold own in faceoff with Amazon
15/03/2022  Knowledge of the local market, strong branding and a growing subscription service should see the undervalued retailer retain market share in the rapidly growing online sales category, says Roy Van Keulen.
"There's been a big rotation in markets": Value surges as growth stumbles
08/03/2022  Higher inflation, rising interest rates and booming commodity markets are driving a major rotation away from the post-pandemic winners, says Tim Murphy, Morningstar director of manager selection.
Afterpay's rivals set for battle with rates and regulators
03/03/2022  Regulators are likely to be less lenient now the buy-now-pay-later sector is part of the fabric of Australian payments.
Industry champions on the cheap: Emerging markets at the Morningstar Investment Conference
23/02/2022  Strong commodity prices, cheap valuations and a head start on interest rate hikes means emerging markets are set for strength, says Dr. Joseph Lai of Ox Capital.
The Russia crisis is heating up, but you need to stay cool
23/02/2022  A belligerent speech from a president signalled the start of the latest phase of Russian agression last night, causing markets to wobble and investors to wonder.
Peter Warnes on FAANGs, investing in Asia and bond market smoke signals
15/02/2022  In an extended interview, Morningstar's Peter Warnes discusses the bear market in US technology stocks, interest rates and growth and his approach to investing outside the US and Australia.
Weighing up Magellan Financial Group after Douglass surprise exit
13/02/2022  Morningstar equity analyst Shaun Ler explains why he see valuation upside high for MFG even as shares lose steam.
Year of the Tiger: What's next for Chinese stocks
31/01/2022  The Chinese lunar year is almost over, and what a ride it's been. Morningstar speaks to JPMorgan Asset Management strategist Mike Bell about what's ahead. 
What to do (and not do) in a volatile market
23/01/2022  Christine Benz discusses how investors should handle the turmoil, whatever the life stage.
Bare shelves only a short-term hit to Coles and Woolies
18/01/2022  Empty shelves will negatively impact supermarkets in the second half of fiscal 2022 but the impact on long-term earnings is minimal, says Morningstar analyst Johannes Faul. 
Morningstar's outlook for 2022
17/01/2022  Bank earnings, house prices and China risk: Our experts and analysts discuss what they've got their eyes on in 2022.
Morningstar's Year in Review 2021
24/12/2021  Our experts and analysts weigh in on what mattered for investors last year.
"A bump in the road" as Magellan loses major client
21/12/2021  New products, lower fees and a portfolio of undervalued stocks set to help the fund manager right the ship. 
What role should Bitcoin play in your portfolio?
10/12/2021  And how does it match up against gold?
Years of demand remain for Australian coal producers
10/12/2021  Australian miners to be among the last standing as coal use fades.
Year-end portfolio rebalancing: What you need to know
08/12/2021  Rebalancing your portfolio is one of those beneficial habits that’s easy to let slide. But year-end is an ideal time to check how your portfolio is tracking against your target asset allocation. 
3 quality names from Stewart Investors
03/12/2021  The gold-rated fund manager shares three ideas with long-term potential.
Silver linings for investors amid the climate stalemate: COP26 debrief
01/12/2021  Long-term investor sees opportunities where businesses are moving towards a zero-carbon future faster than governments.
6 qualities of great index funds
30/11/2021  To understand your fund, get to know its underlying index.
Lazard's 3 top picks for the energy transition
29/11/2021  These companies are set to profit from the move to clean energy, says Lazard.
An uneven energy transition leaves room for coal and gas: COP26 debrief
24/11/2021  The results of the COP26 climate summit suggest coal demand is likely to persist for longer than expected.
What rising inflation means for Australian investors
17/11/2021  And how investors can protect their portfolios.
6 inflation-tough stocks for global investors
08/11/2021  Morningstar thinks these moaty companies will remain resilient in the face of inflation and ongoing supply chain challenges.
Risk/reward equation still looks good at Westpac
05/11/2021  Morningstar maintains fair value despite a fall in margins and slower progress on cost reductions.
These aren't the Bitcoin ETFs you're looking for
19/10/2021  These new US-listed exchange-traded funds will invest in bitcoin futures, not bitcoin itself.
ESG funds don't underperform - but nor do they outperform
15/10/2021  The ESG outperformance narrative is flawed, new research shows.
Building investment portfolios in a low interest rate environment
06/10/2021  Investors may need to hold more growth assets over the coming years, says Morningstar's Jody Fitzgerald.
Covid impacts still being felt in real estate and tech: Reporting season roundup
01/10/2021  And how G8 Education and Link Administration are positioned for long-term success.
Look to Credit Corp for a leading indicator of economic health: Reporting season roundup
30/09/2021  What Reporting Season August 2021 told investors about the health of the financials sector.
Cause for optimism at a2 Milk and Invocare: Reporting season roundup
28/09/2021  a2 milk is an opportunity to be greedy when others are fearful.
Post-covid normalisation is underway in healthcare: Reporting season roundup
23/09/2021  Covid's winners and losers are returning to their prior trajectories. 
One of the most underappreciated dangers of investing
21/09/2021  Sequence-of-returns risk matters for both retirees and savers. Here's why. 
REITs recover pandemic losses: Reporting season roundup
20/09/2021  Analysts expect the sector to recover to pre-Covid trading levels once borders reopen.
Australian banks face margin pressure amid low rates: Reporting season roundup
15/09/2021  Rising customer deposits and access to cheap funding helped Australia's banks stave off net interest margin pressure, but analysts see warning signs.
Greenwashing explained
14/09/2021  Morningstar's Hortense Bioy on how to spot greenwashing and how to avoid it.
Earnings down as private money circles infrastructure: Reporting season roundup
13/09/2021  Utilities and infrastructure names battle the impact of covid as private equity and pension funds circle. 
Frenzy of mergers in energy: Reporting season roundup
10/09/2021  Hydrocarbons poised for a comeback.
TPG tipped to recover as mobile competition eases: Reporting season roundup
09/09/2021  Providers have lifted prices after years of a debilitating chase for subscribers at all costs , says Morningstar's Brian Han.
Short-sellers bet against ARK Innovation ETF
08/09/2021  What shorting ETFs means for long-term investors.
Surging lumber prices were no match for Brambles: Reporting season roundup
07/09/2021  Morningstar senior analyst Grant Slade says Brambles secular growth trend is intact despite nearterm headwinds. He discusses results from the building and construction materials sector.
Miners soar thanks to iron ore: Reporting season roundup
03/09/2021  Miners bask in the glow of iron ore prices while bargains remain in coal.
BHP-Woodside merger is mutually beneficial
23/08/2021  Post-merger Woodside would be well positioned to deliver on the value we've seen for a long time, say Morningstar analysts.
Investors are getting serious about sustainability
16/08/2021  But the sector lacks uniformity, says Morningstar's Christopher Franz. 
Long term outlook for AGL is positive
11/08/2021  Higher wholesale electricity prices bode well for AGL, according to Morningstar senior equities analyst Adrian Atkins.
How you can hedge your portfolio against inflation
11/08/2021  Morningstar FundInvestor editor Russ Kinnel describes some direct and indirect hedges for inflation protection.
The iron ore party can't last: Morningstar
10/08/2021  Copper and iron ore have benefited materially from China’s stimulus and the developed world recovery. But Morningstar analyst Mat Hodge see these benefit as transitory.
What the Afterpay acquisition means for investors: Morningstar Minute
05/08/2021  We believe the transaction has a high chance of succeeding.
Cannabis' federal legal status is not a total buzzkill
03/08/2021  The industry still has significant growth potential.
Stock of the week: Toyota
03/08/2021  Is one of the biggest sponsors of the Olympics positioned for an all-electric future?
2 listed microcap names to consider
23/07/2021  Morningstar's Lex Hall talks micro-cap stock picks with Carlos Gil, chief investment officer at Microequities Asset Management.
Big returns, big risks: Making money with microcaps
22/07/2021  Mornngstar's Lex Hall catches up with Carlos Gil, chief investment officer at Microequities Asset Management.
3 small-caps with Dawn Kanelleas
21/07/2021  The head of Australian small and mid-cap stocks at First Sentier Investors has her eye on ARB, Breville and IDP Education.
Forecast 2021–2022: A correction could be around the corner
20/07/2021  The strong performances of global stock markets in 2020–21 are unlikely to be repeated in the coming year says Morningstar's Peter Warnes.
'Overvalued' warnings grow as ASX 200 hits new high
12/07/2021  Morningstar equity analysts warn that equities remain overvalued despite Australia's strong economic recovery.
What to know about private equity
08/07/2021  Private equity is an exciting area for investors, with lots of hotly-tipped stocks. But there are risks to be aware of, says Pitchbook analyst Dylan Cox.
Lazard's 3 top picks for the global covid recovery
08/07/2021  Warryn Robertson is looking at French infrastructure, retail pharmacy and tax services.
Aussie banks $34bn surplus points to more shareholder dividends, buybacks
06/07/2021  Australia's largest banks have excess capital because they cut dividends, were more conservative on lending, divested assets and raised equity last year. Morningstar's Nathan Zaia thinks most of it should be returned to shareholders.
Weighing up the PEXA IPO
02/07/2021  PEXA burst onto the ASX this week in the biggest float since 2019. Morningstar's Gareth James gives his take on the company's future growth prospects.
Can the iron ore price keep rising?
30/06/2021  Iron ore prices have  been on a tear, boosting the profits of Australia's top miners.  How did we get here and is the only way up? Lex Hall sits down with Morningstar's Mat Hodge.
2 new stocks to watch
28/06/2021  Morningstar has recently initiated coverage of a food delivery app and a consumer finance product. 
'Strongest earnings season I've ever seen'
24/06/2021  Meeting the deluge of demand is the biggest task for US companies, says Bell Asset Management's Ned Bell.
Biotech beyond covid
22/06/2021  Are there still opportunities in the biotech sector now the covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager Ailsa Craig
Alibaba is still deeply undervalued
21/06/2021  Morningstar's director of Asia equity research is confident the e-commerce giant will bounce back.
Weighing up the Endeavour IPO
18/06/2021  A wide moat and attractive dividend potential are among the key takeaways of Woolworth's decision to demerge from the liquor and hospitality group.
'Then we got hit with the equivalent of a war'
15/06/2021  Lazard Asset Management's Warryn Robertson explains how companies in the Global Equity Franchise fund have adjusted to covid, and assesses the threat of rising inflation.
Understanding Magellan's active ETF strategy
11/06/2021  Magellan's Craig Wright tells Emma Rapaport why it is leading the charge in the active ETF arena and how its global equity product works.
3 off-the-radar small caps
10/06/2021  Callum Burns of ICE Investors explains his conviction in pharmaceutical distributor Ebos, PSC Insurance Group, and elite sports analytics provider Catapult.
Small cap gems and how to find them
09/06/2021  Callum Burns explains how ICE Investors identifies companies with original products and sticky customer bases.
Stock of the Week: Salesforce.com
08/06/2021  They’re building an empire.
3 oil stocks we still like
07/06/2021  A year ago the oil price went negative. How have oil giants handled the past 12 months and what's the outlook from here? Morningstar analyst Allen Good explains.
Considering crypto? Here's what to think about
04/06/2021  As the investment world goes crazy for crypto, Morningstar Investment Management's Dan Kemp explains what to consider before putting it in your portfolio
Why we like Wizz Air
03/06/2021  The airline sector is set to recover as international travel resumes. Morningstar analysts think Wizz Air offer the best opportunity among low-cost carriers.
3 global infrastructure picks
28/05/2021  4D Infrastructure's Sarah Shaw outlines the investment case for Spanish multinationals Cellnex, and Iberdrola, and the potential of Mexican airports.